Umifenovir: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 41: | Line 41: | ||
[[Category:Influenza]] | [[Category:Influenza]] | ||
[[Category:COVID-19 pandemic]] | [[Category:COVID-19 pandemic]] | ||
<gallery> | |||
File:Umifenovir Arbidol.svg | |||
File:Umifenovir_ball-and-stick_model.png | |||
</gallery> | |||
Revision as of 02:06, 17 February 2025
Antiviral medication used to treat influenza and other viral infections
Umifenovir, sold under the brand name Arbidol, is an antiviral medication used primarily for the treatment and prevention of influenza and other viral infections. It is known for its ability to inhibit the fusion of the viral membrane with the host cell membrane, thereby preventing the virus from entering the cell and replicating.
Mechanism of Action
Umifenovir acts by inhibiting the fusion of the viral envelope with the cell membrane. This is achieved by targeting the hemagglutinin protein of the virus, which is responsible for the fusion process. By preventing this fusion, umifenovir effectively blocks the entry of the virus into the host cell, thereby halting the infection process.
Uses
Umifenovir is primarily used for the treatment and prevention of influenza A and B. It has also been studied for its potential effectiveness against other viral infections, including coronaviruses and hepatitis C.
Influenza
Umifenovir is used both as a prophylactic and therapeutic agent against influenza. It is believed to reduce the duration and severity of symptoms when administered early in the course of the infection.
Other Viral Infections
Research has explored the use of umifenovir in treating infections caused by other viruses, such as SARS-CoV-2, the virus responsible for COVID-19. However, its efficacy in these cases is still under investigation.
Side Effects
Common side effects of umifenovir include gastrointestinal disturbances such as nausea and diarrhea. It is generally well-tolerated, but as with any medication, adverse reactions can occur.
History
Umifenovir was first developed in Russia in the late 1980s and has been widely used in Russia and China. It gained attention during the COVID-19 pandemic as a potential treatment option, although its effectiveness for COVID-19 remains uncertain.
Research
Numerous studies have been conducted to evaluate the efficacy of umifenovir against various viral infections. While some studies suggest potential benefits, others have shown limited or no effect, particularly in the context of COVID-19.
Related Pages
References
<references group="" responsive="1"></references>
